These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33760297)

  • 1. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65.
    D'Angelo RN; Rahman M; Khanna R; Yeh RW; Goldstein L; Yadalam S; Kalsekar I; Tung P; Zimetbaum PJ
    J Cardiovasc Electrophysiol; 2021 Jun; 32(6):1529-1537. PubMed ID: 33760297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Am J Cardiol; 2015 Feb; 115(3):316-22. PubMed ID: 25491240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
    Friberg L
    Am Heart J; 2018 Nov; 205():118-127. PubMed ID: 30236980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between specific antiarrhythmic drug prescription in the post-procedural blanking period and recurrent atrial arrhythmias after catheter ablation for atrial fibrillation.
    Malladi CL; Darden D; Aldaas O; Mylavarapu PS; Eskander M; Lupercio F; Han FT; Hoffmayer KS; Raissi F; Ho G; Krummen D; Feld GK; Hsu JC
    PLoS One; 2021; 16(6):e0253266. PubMed ID: 34166392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugs.
    Allen LaPointe NM; Dai D; Thomas L; Piccini JP; Peterson ED; Al-Khatib SM
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):292-300. PubMed ID: 25829248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
    Khachatryan A; Merino JL; de Abajo FJ; Botto GL; Kirchhof P; Breithardt G; Stambler B; Abenhaim L; Grimaldi-Bensouda L
    Europace; 2022 Jul; 24(6):899-909. PubMed ID: 34792111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
    Wu C; Tcherny-Lessenot S; Dai W; Wang Y; Kechemir H; Gandhi S; Lin S; Juhaeri J
    Clin Ther; 2018 Mar; 40(3):450-455.e1. PubMed ID: 29500139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study.
    Andersen SS; Hansen ML; Gislason GH; Schramm TK; Folke F; Fosbøl E; Abildstrøm SZ; Madsen M; Køber L; Torp-Pedersen C
    Europace; 2009 Jul; 11(7):886-91. PubMed ID: 19443433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antiarrhythmic medications on the risk of cardiovascular outcomes in patients with atrial fibrillation and coronary artery disease.
    Wang SR; Huang KC; Lin TT; Chuang SL; Yang YY; Wu CK; Lin LY
    Int J Cardiol; 2024 Aug; 409():132198. PubMed ID: 38782070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort.
    Lüker J; Sultan A; Sehner S; Hoffmann B; Servatius H; Willems S; Steven D
    Heart Vessels; 2016 Oct; 31(10):1669-75. PubMed ID: 26546306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline-Concordant Antiarrhythmic Drug Use in the Get With The Guidelines-Atrial Fibrillation Registry.
    Field ME; Holmes DN; Page RL; Fonarow GC; Matsouaka RA; Turakhia MP; Lewis WR; Piccini JP;
    Circ Arrhythm Electrophysiol; 2021 Feb; 14(2):e008961. PubMed ID: 33419385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
    Steinberg BA; Hellkamp AS; Lokhnygina Y; Halperin JL; Breithardt G; Passman R; Hankey GJ; Patel MR; Becker RC; Singer DE; Hacke W; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Piccini JP;
    Heart Rhythm; 2014 Jun; 11(6):925-32. PubMed ID: 24833235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses.
    Calkins H; Reynolds MR; Spector P; Sondhi M; Xu Y; Martin A; Williams CJ; Sledge I
    Circ Arrhythm Electrophysiol; 2009 Aug; 2(4):349-61. PubMed ID: 19808490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs.
    Ornelas-Loredo A; Kany S; Abraham V; Alzahrani Z; Darbar FA; Sridhar A; Ahmed M; Alamar I; Menon A; Zhang M; Chen Y; Hong L; Konda S; Darbar D
    JAMA Cardiol; 2020 Jan; 5(1):57-64. PubMed ID: 31774463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
    Guerra F; Hohnloser SH; Kowey PR; Crijns HJ; Aliot EM; Radzik D; Roy D; Connolly S; Capucci A
    Clin Cardiol; 2014 Dec; 37(12):717-24. PubMed ID: 25470298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis.
    Kim MH; Smith PJ; Jhaveri M; Lin J; Klingman D
    Clin Ther; 2011 Nov; 33(11):1668-1681.e1. PubMed ID: 22108302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.
    Saksena S; Slee A; Waldo AL; Freemantle N; Reynolds M; Rosenberg Y; Rathod S; Grant S; Thomas E; Wyse DG
    J Am Coll Cardiol; 2011 Nov; 58(19):1975-85. PubMed ID: 22032709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
    Wu VC; Wang CL; Huang YC; Tu HT; Huang YT; Huang CH; Chen SW; Kuo CF; Hung KC; Chang SH
    Europace; 2023 May; 25(5):. PubMed ID: 37000581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.